NEET-PG 2015 Practice Questions

Q: What is the posterior relation of the neck of the pancreas?

Origin of portal vein. ***Origin of portal vein*** - The **neck of the pancreas** is intimately associated with the formation of the **hepatic portal vein** [1]. - The **superior mesenteric vein** and **splenic vein** unite behind the pancreatic neck to form the **hepatic portal vein** [1]. *IVC* - The **inferior vena cava (IVC)** lies posterior to the **head of the pancreas**, not the neck. - While it's in proximity, it does not directly relate to the neck in the same way the portal vein does. *Aorta* - The **abdominal aorta** lies posterior to the **body** and **tail of the pancreas**, further superior and to the left. - It is not a direct posterior relation of the pancreatic neck. *Common bile duct* - The **common bile duct** passes through a groove on the posterior surface of the pancreatic **head**, sometimes even embedded within it. - It is not a direct posterior relation of the pancreatic neck, which is a different segment.

Q: A nerve injured during axillary lymph node dissection leads to loss of sensation in the medial side of the arm. Which nerve is injured?

Intercostobrachial nerve. ***Intercostobrachial nerve*** - The **intercostobrachial nerve** (T2) is the nerve most commonly injured during **axillary lymph node dissection** - It provides **sensory innervation to the medial side of the upper arm**, specifically the skin over the medial and posterior aspects of the arm [1] - This nerve arises from the **lateral cutaneous branch of the second intercostal nerve** and crosses the axilla to reach the arm [1] - Injury during axillary surgery results in **numbness or paresthesia** in the medial upper arm region, which is a well-recognized complication of breast cancer surgery with axillary node dissection [1] - Studies show **30-80% of patients** undergoing axillary dissection experience intercostobrachial nerve injury *Long thoracic nerve* - The **long thoracic nerve** (C5-C7) innervates the **serratus anterior muscle**, which is crucial for scapular protraction and rotation - Damage to this nerve causes **"winged scapula"**, where the scapula protrudes posteriorly - This is a **motor nerve**, not sensory, so injury does not result in sensory deficits in the arm *Medial pectoral nerve* - The **medial pectoral nerve** (C8-T1) primarily innervates the **pectoralis major** and **pectoralis minor** muscles [1] - This is a **motor nerve** playing a role in muscle function rather than sensation [1] - Injury would result in weakness of these muscles, not sensory loss *Accessory nerve* - The **accessory nerve** (cranial nerve XI) innervates the **sternocleidomastoid** and **trapezius muscles** - This nerve is located in the **posterior triangle of the neck**, not in the axilla - Injury would lead to weakness in shrugging the shoulders or turning the head, not sensory loss in the arm during axillary dissection

Q: Root value of the thoracodorsal nerve

C6, C7, C8. ***C6, C7, C8*** - The **thoracodorsal nerve**, also known as the middle subscapular nerve, originates from the **posterior cord of the brachial plexus**. - Its specific root values are **C6, C7, and C8**, which supply motor innervation to the **latissimus dorsi muscle** [1]. - This nerve is one of the three subscapular nerves arising from the posterior cord [1]. *C5, C6, C7* - While these roots contribute to the **posterior cord**, the thoracodorsal nerve specifically arises from **C6, C7, C8**. - **C5** primarily contributes to the **upper and middle trunk** and is more associated with nerves like the **suprascapular** and **axillary nerves**. *C6, T1* - These root values contribute to various nerves of the **brachial plexus**, but not specifically the thoracodorsal nerve. - **T1** contributes mainly to the **medial cord** and its branches like the **ulnar nerve**, not the posterior cord from which the thoracodorsal nerve arises. *T1, T2* - These are typical root values for **intercostal nerves** and contribute to the **sympathetic trunk**, not the **brachial plexus** or its branches like the thoracodorsal nerve. - The brachial plexus predominantly arises from **C5 to T1 spinal nerve roots**, and **T2** is not part of the brachial plexus.

Q: What is the immediate source of energy for cellular processes?

ATP. ***ATP*** - **Adenosine triphosphate (ATP)** is the direct and immediate source of energy for almost all cellular processes, including **muscle contraction**, **active transport**, and **biosynthesis**. - Its high-energy phosphate bonds release energy upon hydrolysis, driving various cellular functions. *Cori's cycle* - The **Cori cycle** involves the interconversion of **lactate** and **glucose** between the muscle and the liver to regenerate glucose stores. - It is an important metabolic pathway for glucose homeostasis during anaerobic conditions, but it does not directly provide immediate energy for cellular processes. *HMP* - The **Hexose Monophosphate Pathway (HMP)**, also known as the **pentose phosphate pathway**, primarily produces **NADPH** and **ribose-5-phosphate**. - While it generates NADPH for reductive biosynthesis and protects against oxidative stress, it is not an immediate source of energy. *TCA cycle* - The **Tricarboxylic Acid (TCA) cycle**, or Krebs cycle, is a central metabolic pathway that oxidizes **acetyl-CoA** to produce **ATP**, **NADH**, and **FADH2**. - While it is a major producer of ATP, it is not the *immediate* source; instead, it generates the precursors that fuel oxidative phosphorylation to produce ATP.

Q: Which is the first steroid intermediate formed in the conversion of cholesterol to steroid hormones?

Pregnenolone. ***Pregnenolone*** - **Pregnenolone** is the **first steroid intermediate** formed from **cholesterol** in steroidogenesis - The conversion occurs in mitochondria via the **cholesterol side-chain cleavage enzyme (P450scc/CYP11A1)** - This is the **rate-limiting step** in steroid hormone biosynthesis - From pregnenolone, all other steroid hormones are subsequently synthesized *Progesterone* - Progesterone is the **second intermediate**, formed from pregnenolone - It serves as a precursor for glucocorticoids, mineralocorticoids, and androgens - Not the first intermediate from cholesterol *Glucocorticoid* - Glucocorticoids (e.g., cortisol) are **end products**, not intermediates - Formed several steps downstream from cholesterol via pregnenolone and progesterone *Mineralocorticoid* - Mineralocorticoids (e.g., aldosterone) are **end products**, not intermediates - Synthesized from progesterone through multiple enzymatic steps *Estradiol* - Estradiol is a **late-stage product** synthesized from androgens - Requires aromatase enzyme for conversion from testosterone - Multiple steps removed from the initial cholesterol conversion

Q: Randomization is done to reduce?

Selection bias. ***Selection bias*** - **Randomization** ensures that each participant has an equal chance of being assigned to any study group, which helps to distribute both known and unknown confounding factors evenly. - This process minimizes **selection bias** by promoting comparability between groups, making it more likely that any observed differences are due to the intervention rather than pre-existing differences. *Recall bias* - **Recall bias** occurs when there are systematic differences in the way participants remember or report past exposures or events, often seen in retrospective studies. - While randomization helps control for confounding, it does not directly prevent participants from inaccurately recalling information. *Berksonian bias* - **Berksonian bias** is a form of selection bias where the probability of being admitted to a hospital (or selected into a study) is affected by the presence of a co-morbidity, leading to a distorted association between diseases. - Randomization aims to balance characteristics *within* the study groups once participants are recruited, but it doesn't address biases related to the initial selection into the study population from a larger source. *Reporting bias* - **Reporting bias** refers to selective revealing or suppression of information, either by study participants (e.g., social desirability bias) or by researchers (e.g., only reporting positive findings). - Randomization helps ensure internal validity by creating comparable groups, but it does not prevent individuals from selectively reporting outcomes or experiences.

Q: Which of the following statements about Alport's syndrome is incorrect?

Autosomal dominant. ***Autosomal dominant*** - While there are rare autosomal dominant forms, the most common and classic presentation of **Alport's syndrome is X-linked recessive**, affecting males more severely. - This statement is incorrect because it implies that autosomal dominant inheritance is the primary or typical mode, which is not true for the majority of cases. *Nerve deafness* - **Sensorineural hearing loss**, particularly for high frequencies, is a common and characteristic extra-renal manifestation of Alport's syndrome. - This symptom typically progresses with age and is a key diagnostic feature. *Glomerulonephritis* - **Progressive glomerulonephritis** is the hallmark renal feature of Alport's syndrome, leading to hematuria, proteinuria, and eventually end-stage renal disease. - It is caused by mutations in collagen type IV genes, which disrupt the integrity of the glomerular basement membrane. *X-linked* - The majority of Alport's syndrome cases (about 85%) are **X-linked recessive**, caused by mutations in the *COL4A5* gene located on the X chromosome. - This explains why males are more severely affected and typically present with earlier onset and more rapid progression of renal disease.

Q: XDR-TB is defined as resistance to which of the following drug combinations?

Fluoroquinolones plus INH plus rifampicin plus amikacin. **Fluoroquinolones plus INH plus rifampicin plus amikacin** - **Extensively drug-resistant tuberculosis (XDR-TB)** is defined by resistance to the most effective anti-TB drugs: **isoniazid (INH)**, **rifampicin**, any **fluoroquinolone**, and at least one of the three injectable second-line drugs (**amikacin**, **kanamycin**, or **capreomycin**). - This combination signifies a substantial therapeutic challenge due to limited treatment options and a high risk of treatment failure. *INH plus rifampicin* - Resistance to **INH** and **rifampicin** defines **multidrug-resistant tuberculosis (MDR-TB)**, which is a precursor to XDR-TB but not XDR-TB itself. - While serious, MDR-TB is not as extensively resistant as XDR-TB, as it doesn't include resistance to fluoroquinolones and second-line injectables. *Fluoroquinolones plus INH plus amikacin* - This combination is incomplete for the definition of XDR-TB because it omits **rifampicin** from the core definition. - XDR-TB specifically requires resistance to both **INH** and **rifampicin** (defining MDR-TB), in addition to resistance to a fluoroquinolone and one of the injectable second-line drugs. *Fluoroquinolones plus rifampicin plus kanamycin* - This combination is also incomplete for the definition of XDR-TB as it omits **isoniazid (INH)**, which is one of the two most crucial first-line drugs that characterize MDR-TB. - XDR-TB builds upon MDR-TB's resistance to both INH and rifampicin.

Q: Gastric carcinoma is associated with all of the following EXCEPT:

Activation of RAS. ***Activation of RAS*** - **RAS mutations** are relatively uncommon in gastric carcinoma compared to other gastrointestinal malignancies. While KRAS mutations can occur in approximately 10-15% of gastric cancers (particularly intestinal type), they are **far less frequent** than in **pancreatic adenocarcinoma** (~90%) or **colorectal carcinoma** (~40%). - In the context of gastric carcinoma, RAS pathway alterations are **not considered a major oncogenic driver** compared to the other molecular changes listed, making this the **LEAST characteristically associated** alteration. *Inactivation of p53* - **Inactivation of the p53 tumor suppressor gene** is one of the most frequent molecular events in gastric carcinoma, occurring in approximately **50-60% of cases**. - Loss of p53 function leads to genomic instability, uncontrolled cell proliferation, and resistance to apoptosis, contributing significantly to **tumorigenesis** and **poor prognosis**. *Over expression of C-met* - **Overexpression of C-MET**, a receptor tyrosine kinase for hepatocyte growth factor (HGF), is commonly observed in gastric carcinoma (30-40% of cases) and is strongly linked to **tumor growth**, **invasion**, and **metastasis**. - C-MET amplification and overexpression promote cell proliferation, survival, migration, and angiogenesis, making it an important **therapeutic target** in advanced gastric cancer. *Over expression of C-erb* - **Overexpression of C-erbB-2 (HER2/neu)** is found in approximately **10-20% of gastric adenocarcinomas**, particularly the intestinal type. - HER2 amplification or overexpression is a significant **prognostic and predictive biomarker**, and is specifically targeted by **trastuzumab** (Herceptin) therapy in HER2-positive advanced gastric cancer, improving survival outcomes.

Q: Which dopamine receptor is known for its inhibitory action in the central nervous system?

Dopamine Receptor D2. ***Dopamine Receptor D2*** - The **D2 receptor** is a member of the D2-like family (D2, D3, D4), which are **G-protein coupled receptors** that inhibit adenylyl cyclase activity. - Its activation typically leads to a **decrease in neuronal excitability** and neurotransmitter release, providing an inhibitory effect in the CNS. *Dopamine Receptor D5* - The **D5 receptor** belongs to the D1-like family (D1, D5), which are **G-protein coupled receptors** that stimulate adenylyl cyclase activity. - Activation of D5 receptors typically leads to **excitatory effects** rather than inhibitory ones in the CNS. *No inhibitory dopamine receptor present* - This statement is incorrect as specific dopamine receptor subtypes, particularly the **D2-like family**, are well-established to exert inhibitory actions in the CNS. - These inhibitory effects are crucial for various physiological processes, including motor control and reward pathways. *Dopamine Receptor D1* - The **D1 receptor** is part of the D1-like family (D1, D5) and is known for its **excitatory effects** in the CNS. - Activation of D1 receptors leads to an **increase in intracellular cAMP** and generally enhances neuronal activity.

Question 1

What is the posterior relation of the neck of the pancreas?

Accepted Answer

Origin of portal vein

Answer

IVC

Answer

Aorta

Answer

Common bile duct

Question 2

A nerve injured during axillary lymph node dissection leads to loss of sensation in the medial side of the arm. Which nerve is injured?

Accepted Answer

Intercostobrachial nerve

Answer

Long thoracic nerve

Answer

Medial pectoral nerve

Answer

Accessory nerve

Question 3

Root value of the thoracodorsal nerve

Accepted Answer

C6, C7, C8

Answer

T1, T2

Answer

C5, C6, C7

Answer

C6, T1

Question 4

What is the immediate source of energy for cellular processes?

Accepted Answer

ATP

Answer

Cori's cycle

Answer

HMP

Answer

TCA cycle

Question 5

Which is the first steroid intermediate formed in the conversion of cholesterol to steroid hormones?

Accepted Answer

Pregnenolone

Answer

Glucocorticoid

Answer

Mineralocorticoid

Answer

Estradiol

Question 6

Randomization is done to reduce?

Accepted Answer

Selection bias

Answer

Recall bias

Answer

Berksonian bias

Answer

Reporting bias

Question 7

Which of the following statements about Alport's syndrome is incorrect?

Accepted Answer

Autosomal dominant

Answer

Nerve deafness

Answer

Glomerulonephritis

Answer

X-linked

Question 8

XDR-TB is defined as resistance to which of the following drug combinations?

Accepted Answer

Fluoroquinolones plus INH plus rifampicin plus amikacin

Answer

INH plus rifampicin

Answer

Fluoroquinolones plus INH plus amikacin

Answer

Fluoroquinolones plus rifampicin plus kanamycin

Question 9

Gastric carcinoma is associated with all of the following EXCEPT:

Accepted Answer

Activation of RAS

Answer

Over expression of C-met

Answer

Inactivation of p53

Answer

Over expression of C-erb

Question 10

Which dopamine receptor is known for its inhibitory action in the central nervous system?

Accepted Answer

Dopamine Receptor D2

Answer

Dopamine Receptor D5

Answer

No inhibitory dopamine receptor present

Answer

Dopamine Receptor D1

NEET-PG 2015

Anatomy

Biochemistry

Community Medicine

Internal Medicine

Microbiology

Pathology

Pharmacology